SCHEMBL5225462

SCHEMBL5225462

Cc1ccccc1-c1nc(S(C)(=O)=O)nc2c1C(=O)N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)CCCN2

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SDHB P21912 1/20 0.40
TACR1 P25103 15/20 0.39
ADRB2 P07550 1/20 0.36
FPR1 P21462 1/20 0.36
GPR183 P32249 1/20 0.36
APLNR P35414 1/20 0.36
GLP1R P43220 1/20 0.36
GPBAR1 Q8TDU6 1/20 0.36
GPR35 Q9HC97 1/20 0.36
PSEN1 P49768 2/20 0.34
PSEN2 P49810 2/20 0.34
APH1B Q8WW43 2/20 0.34
NCSTN Q92542 2/20 0.34
APH1A Q96BI3 2/20 0.34
PSENEN Q9NZ42 2/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5226972 0.96 SDHB (0.40) SDHBTACR1ADRB2FPR1GPR183
SCHEMBL5231461 0.90 HPGD (0.42) SDHBTACR1ADRB2FPR1GPR183
SCHEMBL5228204 0.89 TACR1 (0.41) SDHBTACR1ADRB2FPR1GPR183
SCHEMBL5230402 0.87 TACR1 (0.40) TACR1ADRB2FPR1GPR183APLNR
SCHEMBL5230860 0.86 TACR1 (0.41) TACR1GPBAR1PSEN1PSEN2APH1B
SCHEMBL5225834 0.86 TACR1 (0.44) TACR1ADRB2FPR1GPR183APLNR
SCHEMBL5225857 0.85 TACR1 (0.40) SDHBTACR1PSEN1PSEN2APH1B
SCHEMBL5232743 0.85 TACR1 (0.40) SDHBTACR1ADRB2FPR1GPR183
SCHEMBL5232800 0.84 TACR1 (0.38) TACR1ADRB2FPR1GPR183APLNR
SCHEMBL5232458 0.83 TACR1 (0.40) TACR1GPBAR1PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1496059-B1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES KYORIN SEIYAKU KK (JP) 2007-08-15 EP disclosed
EP-1496059-B1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES KYORIN SEIYAKU KK (JP) 2007-08-15 EP disclosed
US-7064119-B2 Fused bicyclic pyrimidine derivatives KYORIN PHARMACEUTICAL CO., LTD. (JP) 2006-06-20 US disclosed
US-20050159409-A1 Fused bicyclic pyrimidine derivatives KYORIN PHARMACEUTICAL CO. LTD. (JP) 2005-07-21 US disclosed
EP-1496059-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES Kyorin Pharmaceutical Co., Ltd. (JP) 2005-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159409-A1 Fused bicyclic pyrimidine derivatives BDKRB1, BDKRB2, TACR1 SDHB 3944/4885TACR1 3/4885ADRB2 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.